Aytu Biopharma IncNASDAQ:AYTU
- LAST PRICE1.5082
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4400/ 8
- Ask / Lots1.6000/ 5
- Open / Previous Close--- / 1.5082
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AYTU |
|---|---|---|
| 09:32 ET | 3858 | 1.51 |
| 09:50 ET | 150 | 1.5103 |
| 10:11 ET | 182 | 1.49 |
| 10:15 ET | 2964 | 1.4606 |
| 10:24 ET | 600 | 1.49 |
| 10:26 ET | 793 | 1.5 |
| 10:51 ET | 4000 | 1.52 |
| 10:58 ET | 243 | 1.5 |
| 11:48 ET | 300 | 1.495 |
| 12:06 ET | 150 | 1.52 |
| 12:19 ET | 2000 | 1.5192 |
| 12:35 ET | 100 | 1.4868 |
| 01:20 ET | 100 | 1.47 |
| 01:40 ET | 1000 | 1.471 |
| 02:12 ET | 1835 | 1.46 |
| 02:52 ET | 536 | 1.48 |
| 03:01 ET | 120 | 1.49 |
| 03:06 ET | 649 | 1.49 |
| 03:19 ET | 2091 | 1.45 |
| 03:21 ET | 230 | 1.5038 |
| 03:37 ET | 712 | 1.4706 |
| 03:57 ET | 1400 | 1.45 |
| 04:00 ET | 1000 | 1.5082 |
Nov 13, 2024
DJ Aytu BioPharma Names Ryan Selhorn as CFO, from 6:53PM ET on Wednesday Nov 13, 2024 by Dow Jones
6:53PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Aytu BioPharma Terminates Mark K. Oki as CFO, from 6:25PM ET on Wednesday Nov 13, 2024 by Dow Jones
6:25PM ET on Wednesday Nov 13, 2024 by Dow JonesAytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results, from 4:07PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:07PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 6, 2024
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024, from 5:20PM ET on Wednesday Nov 06, 2024 by Dow Jones
5:20PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aytu Biopharma Inc | 9.3M | -1.2x | --- |
Wuhan General Group (China) Inc | 60.0 | 0.0x | --- |
Fortress Biotech Inc | 43.3M | -0.4x | --- |
MEI Pharma Inc | 18.7M | -0.4x | --- |
Sorrento Therapeutics Inc | 1.7M | 0.0x | --- |
MDxHealth SA | 84.6M | -1.1x | --- |
Company Information
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Contact Information
- Headquarters
- 7900 E. Union Avenue, Suite 920DENVER, CO, United States 80237
- Phone
- 720-437-6580
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- John Donofrio
- Chief Executive Officer, Director
- Joshua Disbrow
- Chief Financial Officer, Treasurer, Corporate Secretary
- Ryan Selhorn
- Chief Commercial Officer
- Greg Pyszczymuka
- Independent Director
- Carl Dockery
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.3M |
|---|---|
Revenue (TTM) | $75.5M |
Shares Outstanding | 6.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.41 |
EPS | $-1.26 |
Book Value | $4.64 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | 11.1x |
Operating Margin | -6.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
